Idera Pharmaceuticals $IDRA fell sharply amid heavy trading volume in response to its pricing of the secondary offering of 25M shares of common stock at $2. Underwriters will be eligible to purchase an additional 3.75mn shares. The closing date is October 13. The net proceeds will go towards the clinical development of pipeline candidates.